Drug intelligence / Profile preview

Pivit

Development stage: Preclinical
Lead developer: Olfactive Biosolutions
Modality: Small Molecules
Administration: Oral

Overview

Pivit is an oral nutraceutical supplement developed by Olfactive Biosolutions for weight management and metabolic health. It is formulated using a proprietary blend of food-derived small molecules designed to activate ectopic olfactory and taste receptors within the gastrointestinal tract. This activation triggers the natural, endogenous secretion of three key metabolic hormones: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and peptide YY (PYY). By functioning as a triple receptor agonist through this indirect mechanism, Pivit aims to reduce appetite and slow gastric emptying. It is positioned as a cost-effective, non-pharmaceutical alternative to injectable GLP-1 therapies with a favorable safety profile.

Brand names: Pivit

Targets

OR (Olfactory receptors)

Beyond the preview

Go deeper on Pivit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pivit.

Explore the full profile